Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Description

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Conditions

Stage III Colon Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Condition
Stage III Colon Cancer
Intervention / Treatment

-

Contacts and Locations

Birmingham

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States, 35233

Fairhope

Thomas Hospital, Fairhope, Alabama, United States, 36532

Mobile

Mobile Infirmary Medical Center, Mobile, Alabama, United States, 36607

Mobile

University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States, 36688

Kingman

Kingman Regional Medical Center, Kingman, Arizona, United States, 86401

Phoenix

Cancer Center at Saint Joseph's, Phoenix, Arizona, United States, 85004

Phoenix

Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States, 85054

Tucson

Banner University Medical Center - Tucson, Tucson, Arizona, United States, 85719

Tucson

University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States, 85719

Fort Smith

Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States, 72903

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Absolute neutrophil count (ANC) must be greater than or equal to 1500/mm3;
  • * Participants with benign ethnic neutropenia (BEN): ANC less than 1300 mm3 are eligible.
  • * BEN (also known as constitutional neutropenia) is an inherited cause of mild or moderate neutropenia that is not associated with any increased risk for infections or other clinical manifestations. BEN is referred to as ethnic neutropenia because of its increased prevalence in people of African descent and other specific ethnic groups.
  • * Platelet count must be greater than or equal to 100,000/mm3; and
  • * Hemoglobin must be greater than or equal to 9 g/dL.
  • * total bilirubin must be less than or equal to ULN (upper limit of normal) for the lab and
  • * alkaline phosphatase must be less than 2.5 x ULN for the lab; and
  • * AST and ALT must be less than 2.5 x ULN for the lab.
  • * Absolute neutrophil count (ANC) must be greater than or equal to 1500/mm3;
  • * Participants with benign ethnic neutropenia (BEN): ANC less than 1300 mm3 are eligible.
  • * BEN (also known as constitutional neutropenia) is an inherited cause of mild or moderate neutropenia that is not associated with any increased risk for infections or other clinical manifestations. BEN is referred to as ethnic neutropenia because of its increased prevalence in people of African descent and other specific ethnic groups.
  • * Platelet count must be greater than or equal to 100,000/mm3; and
  • * Hemoglobin must be greater than or equal to 9 g/dL.
  • * total bilirubin must be less than or equal to ULN (upper limit of normal) for the lab and
  • * alkaline phosphatase must be less than 2.5 x ULN for the lab; and
  • * AST and ALT must be less than 2.5 x ULN for the lab.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

NRG Oncology,

Study Record Dates

2030-03-10